VNDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.900

Open

7.675

VWAP

8.00

Vol

333.00K

Mkt Cap

459.00M

Low

7.675

Amount

3.00M

EV/EBITDA(TTM)

--

Total Shares

59.00M

EV

166.00M

EV/OCF(TTM)

--

P/S(TTM)

2.00

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Show More

Events Timeline

(ET)

2026-01-08

07:20:00

Vanda Pharmaceuticals Shares Drop 11% to $7.55 After FDA Rejects sNDA for Hetlioz

2026-01-08

07:10:00

Vanda Pharmaceuticals' hetlioz Application for Jet Lag Treatment Denied by FDA

2025-12-31 (ET)

2025-12-31

16:30:00

S&P 500 Ends Year Up About 17% as New Year's Eve Session Declines

2025-12-31

12:00:00

Stocks Slightly Lower as S&P 500 Set to Finish Year Up About 17%

2025-12-31

09:10:00

Stock Futures Indicate Modest Market Pullback

News

an image of PRnewswire

15:56 PMPRnewswire

Vanda Pharmaceuticals Under Investigation for Securities Fraud Claims

an image of NASDAQ.COM

01-28NASDAQ.COM

FDA Approves Zycubo for Pediatric Menkes Disease Treatment

an image of Globenewswire

01-20Globenewswire

Vanda Pharmaceuticals Under Investigation After 14.05% Stock Drop Following FDA Decision

an image of Newsfilter

01-08Newsfilter

Vanda Pharmaceuticals' HETLIOZ® Faces Delay as FDA Rejects Current Efficacy Evidence

an image of Newsfilter

01-06Newsfilter

Vanda Pharmaceuticals Receives FDA Approval for Motion Sickness Drug, Analysts Raise Price Targets

an image of Benzinga

Vanda Pharmaceuticals' Nereus Approved by FDA as First New Motion Sickness Drug in 40 Years

4 Analyst Rating

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 13.63 USD with a low forecast of 7.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.50

Averages

13.63

High

22.00

Current: 0.000

Low

7.50

Averages

13.63

High

22.00

H.C. Wainwright

H.C. Wainwright

maintain

$22

AI Analysis

2026-01-08

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$22

AI Analysis

2026-01-08

maintain

Reason

H.C. Wainwright notes that Vanda Pharmaceuticals announced that it has received a decision letter from the FDA's Center for Drug Evaluation and Research concluding that the supplemental New Drug Application for HETLIOZ - tasimelteon - for the treatment of jet lag disorder cannot be approved in its current form. In the firm's view, the rejection of tasimelteon constitutes only a minor setback and may not mark the end of dialogue over the compound in this indication. Furthermore, Wainwright draws investors' attention to the fact that its valuation assessment did not include any contribution from sales of tasimelteon in treatment of jet lag. Accordingly, the firm reiterates a Buy rating and a price target of $22 on the shares.

H.C. Wainwright

Buy

maintain

$20 -> $22

2026-01-05

Reason

H.C. Wainwright

Price Target

$20 -> $22

2026-01-05

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Vanda Pharmaceuticals to $22 from $20 and keeps a Buy rating on the shares. The firm cites the addition of tradipitant sales into the model following the approval for the treatment of motion sickness for the target boost.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNDA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA.O) is -3.33, compared to its 5-year average forward P/E of -20.02. For a more detailed relative valuation and DCF analysis to assess Vanda Pharmaceuticals Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-20.02

Current PE

-3.33

Overvalued PE

157.16

Undervalued PE

-197.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

4.73

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.45

Undervalued EV/EBITDA

-1.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

1.95

Current PS

1.90

Overvalued PS

2.78

Undervalued PS

1.12

Financials

AI Analysis

Annual

Quarterly

Whales Holding VNDA

Tang Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Vanda Pharmaceuticals Inc (VNDA) stock price today?

The current price of VNDA is 7.825 USD — it has increased 1.76 % in the last trading day.

What is Vanda Pharmaceuticals Inc (VNDA)'s business?

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

What is the price predicton of VNDA Stock?

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is13.63 USD with a low forecast of 7.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Vanda Pharmaceuticals Inc (VNDA)'s revenue for the last quarter?

Vanda Pharmaceuticals Inc revenue for the last quarter amounts to 56.00M USD, increased 18.06 % YoY.

What is Vanda Pharmaceuticals Inc (VNDA)'s earnings per share (EPS) for the last quarter?

Vanda Pharmaceuticals Inc. EPS for the last quarter amounts to -0.38 USD, increased 322.22 % YoY.

How many employees does Vanda Pharmaceuticals Inc (VNDA). have?

Vanda Pharmaceuticals Inc (VNDA) has 368 emplpoyees as of January 29 2026.

What is Vanda Pharmaceuticals Inc (VNDA) market cap?

Today VNDA has the market capitalization of 459.00M USD.